TABLE OF CONTENTS
Volume 23, Issue 6 (June 2009)
Original Articles
Molecular Targets for Therapy
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
C Flotho, R Claus, C Batz, M Schneider, I Sandrock, S Ihde, C Plass, C M Niemeyer and M Lübbert
Leukemia 23: 1019-1028; advance online publication, February 5, 2009; doi:10.1038/leu.2008.397
Acute Leukemias
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia
N Gallay, C Dos Santos, L Cuzin, M Bousquet, V Simmonet Gouy, C Chaussade, M Attal, B Payrastre, C Demur and C Récher
Leukemia 23: 1029-1038; advance online publication, January 22, 2009; doi:10.1038/leu.2008.395
Vasculogenic mimicry of acute leukemic bone marrow stromal cells
P Mirshahi, A Rafii, L Vincent, A Berthaut, R Varin, G Kalantar, C Marzac, O A Calandini, J-P Marie, C Soria, J Soria and M Mirshahi
Leukemia 23: 1039-1048; advance online publication, April 2, 2009; doi:10.1038/leu.2009.10
Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations
A Zebisch, M Haller, K Hiden, T Goebel, G Hoefler, J Troppmair and H Sill
Leukemia 23: 1049-1053; advance online publication, April 9, 2009; doi:10.1038/leu.2009.68
Chronic Myeloproliferative Neoplasias
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A Hochhaus, S G O'Brien, F Guilhot, B J Druker, S Branford, L Foroni, J M Goldman, M C Müller, J P Radich, M Rudoltz, M Mone, I Gathmann, T P Hughes and R A Larson for the IRIS Investigators
Leukemia 23: 1054-1061; advance online publication, March 12, 2009; doi:10.1038/leu.2009.38
Chronic Lymphocytic Leukemia
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia
D Rossi, C Lobetti Bodoni, E Genuardi, L Monitillo, D Drandi, M Cerri, C Deambrogi, I Ricca, A Rocci, S Ferrero, E Bernocco, D Capello, L De Paoli, L Bergui, M Boi, P Omedè, M Massaia, C Tarella, R Passera, M Boccadoro, G Gaidano and M Ladetto
Leukemia 23: 1062-1072; advance online publication, April 2, 2009; doi:10.1038/leu.2008.399
Minimal Residual Disease
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol
V H J Van der Velden, L Corral, M G Valsecchi, M W J C Jansen, P De Lorenzo, G Cazzaniga, E R Panzer-Grümayer, M Schrappe, A Schrauder, C Meyer, R Marschalek, L L Nigro, M Metzler, G Basso, G Mann, M L Den Boer, A Biondi, R Pieters and J J M Van Dongen
Leukemia 23: 1073-1079; advance online publication, February 12, 2009; doi:10.1038/leu.2009.17
Normal Hemopoiesis
Caspase activation is involved in early megakaryocyte differentiation but not in platelet production from megakaryocytes
Y Kozuma, S Yuki, H Ninomiya, T Nagasawa and H Kojima
Leukemia 23: 1080-1086; advance online publication, February 12, 2009; doi:10.1038/leu.2009.7
Sensitivity and Resistance to Therapy
Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity
S Halwachs, I Schäfer, P Seibel and W Honscha
Leukemia 23: 1087-1097; advance online publication, February 12, 2009; doi:10.1038/leu.2009.6
Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells
T Rückrich, M Kraus, J Gogel, A Beck, H Ovaa, M Verdoes, H S Overkleeft, H Kalbacher and C Driessen
Leukemia 23: 1098-1105; advance online publication, February 19, 2009; doi:10.1038/leu.2009.8
Oncogenes, Fusion Genes and Tumor Suppressor Genes
Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients
F Weerkamp, E Dekking, Y Y Ng, V H J van der Velden, H Wai, S Böttcher, M Brüggemann, A J van der Sluijs, A Koning, N Boeckx, N Van Poecke, P Lucio, A Mendonça, L Sedek, T Szczepa
ski, T Kalina, M Kovac, P G Hoogeveen, J Flores-Montero, A Orfao, E Macintyre, L Lhermitte, R Chen, K A J Brouwer-De Cock, A van der Linden, A L Noordijk, W M Comans-Bitter, F J T Staal and J J M van Dongen On behalf of the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708)
Leukemia 23: 1106-1117; advance online publication, April 23, 2009; doi:10.1038/leu.2009.93
Lymphoma
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21
D Rossi, S Rasi, S Franceschetti, D Capello, A Castelli, L De Paoli, A Ramponi, A Chiappella, E M Pogliani, U Vitolo, I Kwee, F Bertoni, A Conconi and G Gaidano
Leukemia 23: 1118-1126; advance online publication, January 29, 2009; doi:10.1038/leu.2008.398
Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study
J T Sandlund, C-H Pui, Y Zhou, F G Behm, M Onciu, B I Razzouk, N Hijiya, D Campana, M M Hudson and R C Ribeiro
Leukemia 23: 1127-1130; advance online publication, February 5, 2009; doi:10.1038/leu.2008.400
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation
L Farina, B Bruno, F Patriarca, F Spina, R Sorasio, M Morelli, R Fanin, M Boccadoro and P Corradini
Leukemia 23: 1131-1138; advance online publication, February 5, 2009; doi:10.1038/leu.2009.1
Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies
J Iqbal, C Kucuk, R J deLeeuw, G Srivastava, W Tam, H Geng, D Klinkebiel, J K Christman, K Patel, K Cao, L Shen, K Dybkaer, I F L Tsui, H Ali, N Shimizu, W Y Au, W L Lam and W C Chan
Leukemia 23: 1139-1151; advance online publication, February 5, 2009; doi:10.1038/leu.2009.3
Myeloma
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
E Kastritis, K Zervas, A Symeonidis, E Terpos, S Delimbassi, N Anagnostopoulos, E Michali, A Zomas, E Katodritou, D Gika, A Pouli, D Christoulas, M Roussou, Z Kartasis, T Economopoulos and M A Dimopoulos
Leukemia 23: 1152-1157; advance online publication, February 19, 2009; doi:10.1038/leu.2008.402
Letters to the Editor
Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia
D Rea, E Raffoux, J-M Cayuela, O Maarek and H Dombret
Leukemia 23: 1158-1159; advance online publication, January 8, 2009; doi:10.1038/leu.2008.376
miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities
M Mraz, K Malinova, J Kotaskova, S Pavlova, B Tichy, J Malcikova, K Stano Kozubik, J Smardova, Y Brychtova, M Doubek, M Trbusek, J Mayer and S Pospisilova
Leukemia 23: 1159-1163; advance online publication, January 22, 2009; doi:10.1038/leu.2008.377
Therapy-related acute myeloid leukaemia with t(8;16)(p11;p13);MOZ-CBP and polymorphisms in detoxifying and DNA repair genes
E M Boyd, A J Bench, K J Vaghela, G N Campbell, F B Chowdhury, E J Gudgin, M A Scott and W N Erber
Leukemia 23: 1164-1167; advance online publication, January 22, 2009; doi:10.1038/leu.2008.383
Depletion of L-asparagine supply and apoptosis of leukemia cells induced by human glycosylasparaginase
E Kelo, T Noronkoski and I Mononen
Leukemia 23: 1167-1171; advance online publication, January 22, 2009; doi:10.1038/leu.2008.387
Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase
Y Luo, X-Y Lai, Y-M Tan, J-M Shi, Y-M Zhao, X-Y Han, G-F Zheng, X-L Zhu, J Sun, Y-L Zheng, G-Q Wu, J-S He, S-Y Chen, A-Y Jin, W-Z Xie, X-J Ye, Z Cai, M-F Lin and H Huang
Leukemia 23: 1171-1174; advance online publication, February 5, 2009; doi:10.1038/leu.2008.401
Hypermethylation of Death-Associated Protein Kinase 1 differentiates natural killer cell lines from cell lines derived from T-acute lymphoblastic leukemia
S Röhrs, J Romani, M Zaborski, H G Drexler and H Quentmeier
Leukemia 23: 1174-1176; advance online publication, February 12, 2009; doi:10.1038/leu.2009.5
In situ localization of follicular lymphoma: evidence for subclinical systemic disease with detection of an identical BCL-2/IGH fusion gene in blood and lymph node
M C Cheung, D Bailey, N Pennell, K R Imrie, N L Berinstein, D Amato and Z Ghorab
Leukemia 23: 1176-1179; advance online publication, February 12, 2009; doi:10.1038/leu.2009.9
Ectopic expression of the HLXB9 gene is associated with an altered nuclear position in t(7;12) leukaemias
E Ballabio, C D Cantarella, C Federico, P Di Mare, G Hall, J Harbott, J Hughes, S Saccone and S Tosi
Leukemia 23: 1179-1182; advance online publication, February 12, 2009; doi:10.1038/leu.2009.15
The CLLU1 expression level is a stable and inherent feature of the chronic lymphocytic leukemia clone
A M Buhl, G W Novotny, P Josefsson, J E Nielsen, L B Pedersen, C Geisler, L Z Rassenti, T J Kipps, J Jurlander and H Leffers
Leukemia 23: 1182-1186; advance online publication, February 12, 2009; doi:10.1038/leu.2009.16
SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis
R Chaligné, C Tonetti, R Besancenot, C Marty, J-J Kiladjian, G Socié, D Bordessoule, W Vainchenker and S Giraudier for the FIM (French Intergroup for MPD)
Leukemia 23: 1186-1190; advance online publication, February 19, 2009; doi:10.1038/leu.2009.22
t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals
Y Lecluse, P Lebailly, S Roulland, A-C Gac, B Nadel and P Gauduchon
Leukemia 23: 1190-1193; advance online publication, February 26, 2009; doi:10.1038/leu.2009.31
Imatinib dose escalation for chronic phase–chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy
D Rea, G Etienne, S Corm, P Cony-Makhoul, M Gardembas, L Legros, V Dubruille, S Hayette, F-X Mahon, J-M Cayuela and F E Nicolini
Leukemia 23: 1193-1196; advance online publication, February 26, 2009; doi:10.1038/leu.2009.32
Genes encoding multiple forms of phospholipase A2 are expressed in immature forms of human leukemic blasts
R Fiancette, C Vincent, M Donnard, D Bordessoule, P Turlure, F Trimoreau and Y Denizot
Leukemia 23: 1196-1199; advance online publication, March 5, 2009; doi:10.1038/leu.2009.36
A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response
M W Drummond, N Heaney, J Kaeda, F E Nicolini, R E Clark, G Wilson, P Shepherd, J Tighe, L McLintock, T Hughes and T L Holyoake
Leukemia 23: 1199-1201; advance online publication, March 5, 2009; doi:10.1038/leu.2009.43
Translocation t(14;18) is not associated with inferior outcome in chronic lymphocytic leukemia
N Put, P Meeus, B Chatelain, K Rack, N Boeckx, F Nollet, C Graux, E Van Den Neste, A Janssens, V Madoe, A Van Hoof, C Bilhou-Nabera, I Wlodarska, P Vandenberghe and L Michaux
Leukemia 23: 1201-1204; advance online publication, March 19, 2009; doi:10.1038/leu.2009.44
